Retrieve available abstracts of 55 articles: HTML format
Single Articles
July 2025
SEO JW, Kim JY, Ha YJ, Tak KH, et al Prognostic and therapeutic value of a 23-gene risk score tailored to the
molecular characteristics of mucinous colorectal cancer.
Br J Cancer. 2025 Jul 2. doi: 10.1038/s41416-025-03104. PubMedAbstract available
June 2025
MESA-EGUIAGARAY I, Iakovliev A, Li X, Timofeeva M, et al Association between methylation quantitative trait loci and colorectal cancer
risk, survival and cancer recurrence.
Br J Cancer. 2025 Jun 12. doi: 10.1038/s41416-025-03064. PubMedAbstract available
ZHONG W, Zhang Y, Wang W, Shao Z, et al TRIM26 deficiency potentially suppresses colorectal cancer liver metastasis
through NF-kappaB-mediated M1-like tumor-associated macrophage polarization.
Br J Cancer. 2025 Jun 9. doi: 10.1038/s41416-025-03072. PubMedAbstract available
RUBIO-CUESTA B, Carretero-Puche C, Llamas P, Sarmentero J, et al Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer.
Br J Cancer. 2025 Jun 6. doi: 10.1038/s41416-025-03058. PubMedAbstract available
ANDEL D, Nouwens AJ, Klaassen S, Laoukili J, et al Rational design of alternative treatment options for radioresistant rectal cancer
using patient-derived organoids.
Br J Cancer. 2025;132:973-981. PubMedAbstract available
April 2025
YUAN F, Jia G, Wen W, Xu S, et al Blood metabolic biomarkers and colorectal cancer risk: results from large
prospective cohort and Mendelian randomisation analyses.
Br J Cancer. 2025 Apr 30. doi: 10.1038/s41416-025-02997. PubMedAbstract available
REITSAM NG, Markl B Stroma AReactive Invasion Front Areas (SARIFA) and the tumour immune
microenvironment in colorectal cancer.
Br J Cancer. 2025 Apr 26. doi: 10.1038/s41416-025-03034. PubMed
LEE HJ, Park SW, Lee JH, Chang SY, et al Correction: Differential cellular origins of the extracellular matrix of tumor
and normal tissues according to colorectal cancer subtypes.
Br J Cancer. 2025 Apr 11. doi: 10.1038/s41416-025-02988. PubMed
HASJIM BJ, Ostowari A, Gandawidjaja M, Mohammadi MD, et al De novo colorectal cancer after kidney transplantation: a systematic review and
meta-analysis.
Br J Cancer. 2025 Apr 5. doi: 10.1038/s41416-025-02994. PubMedAbstract available
ELOMAA H, Tarkiainen V, Aijala VK, Sirnio P, et al Associations of mucinous differentiation and mucin expression with immune cell
infiltration and prognosis in colorectal adenocarcinoma.
Br J Cancer. 2025;132:660-669. PubMedAbstract available
March 2025
GRANCHER A, Beaussire-Trouvay L, Vernon V, Dutherage M, et al ctDNA variations according to treatment intensity in first-line metastatic
colorectal cancer.
Br J Cancer. 2025 Mar 15. doi: 10.1038/s41416-025-02971. PubMedAbstract available
TANG F, Zhu Y, Shen J, Yuan B, et al CD44(+) cells enhance pro-tumor stroma in the spatial landscape of colorectal
cancer leading edge.
Br J Cancer. 2025 Mar 12. doi: 10.1038/s41416-025-02968. PubMedAbstract available
TAPIAINEN VV, Sirnio P, Elomaa H, Karjalainen H, et al Stroma AReactive Invasion Front Areas (SARIFA), tumour immune microenvironment,
and survival in colorectal cancer.
Br J Cancer. 2025 Mar 7. doi: 10.1038/s41416-025-02972. PubMedAbstract available
LEE HJ, Park SW, Lee JH, Chang SY, et al Differential cellular origins of the extracellular matrix of tumor and normal
tissues according to colorectal cancer subtypes.
Br J Cancer. 2025 Mar 3. doi: 10.1038/s41416-025-02964. PubMedAbstract available
February 2025
ZHANG Y, Wu D, Zhang Z, Ma J, et al Correction: Impact of lymph node metastasis on immune microenvironment and
prognosis in colorectal cancer liver metastasis: insights from multiomics
profiling.
Br J Cancer. 2025 Feb 17. doi: 10.1038/s41416-025-02941. PubMed
BUNDRED J, Lal N, Chan DKH, Buczacki SJA, et al Lymph node yield as a surrogate marker for tumour biology and prognosis in colon
cancer.
Br J Cancer. 2025 Feb 14. doi: 10.1038/s41416-025-02949. PubMedAbstract available
KATO Y, Seishima R, Hattori K, Kato H, et al Significance of homologous recombinant deficiency as a biomarker for drug
sensitivity in colorectal cancer.
Br J Cancer. 2025 Feb 11. doi: 10.1038/s41416-025-02950. PubMedAbstract available
January 2025
ZHANG Y, Wu D, Zhang Z, Ma J, et al Impact of lymph node metastasis on immune microenvironment and prognosis in
colorectal cancer liver metastasis: insights from multiomics profiling.
Br J Cancer. 2025 Jan 3. doi: 10.1038/s41416-024-02921. PubMedAbstract available
December 2024
LIU C, Reger M, Fan H, Wang J, et al Dietary intake of isoflavones and coumestrol and risk of pancreatic cancer in the
prostate, lung, colorectal, and ovarian cancer screening trial.
Br J Cancer. 2024 Dec 16. doi: 10.1038/s41416-024-02929. PubMedAbstract available
November 2024
PRETTA A, Ziranu P, Perissinotto E, Ghelardi F, et al Early onset metastatic colorectal cancer patients as a distinctive clinical and
molecular phenomenon.
Br J Cancer. 2024 Nov 27. doi: 10.1038/s41416-024-02902. PubMedAbstract available
CHAN WC, Liu L, Bouras E, Zuber V, et al Associations of blood lipids and LDL cholesterol lowering drug-targets with
colorectal cancer risk: a Mendelian randomisation study.
Br J Cancer. 2024 Nov 23. doi: 10.1038/s41416-024-02900. PubMedAbstract available
POGHOSYAN S, Frenkel N, van den Bent L, Raats D, et al VEGF-C propagates 'onward' colorectal cancer metastasis from liver to lung.
Br J Cancer. 2024 Nov 9. doi: 10.1038/s41416-024-02892. PubMedAbstract available
CAMPOS GUDINO R, Neudorf NM, Andromidas D, Lichtensztejn Z, et al Loss of EMI1 compromises chromosome stability and is associated with cellular
transformation in colonic epithelial cell contexts.
Br J Cancer. 2024;131:1516-1528. PubMedAbstract available
October 2024
LI B, Yang W, Liu N, Bi D, et al Phase II Study of Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab
as a Later-line Therapy for Patients with Metastatic Colorectal Cancer (mCRC): a
prospective single-center explorative study.
Br J Cancer. 2024 Oct 24. doi: 10.1038/s41416-024-02885. PubMedAbstract available
OGAARD N, Jensen SO, Orntoft MW, Demuth C, et al Circulating tumour DNA and risk of recurrence in patients with asymptomatic
versus symptomatic colorectal cancer.
Br J Cancer. 2024 Oct 10. doi: 10.1038/s41416-024-02867. PubMedAbstract available
NOH H, Lee J, Seyed Khoei N, Peruchet-Noray L, et al Serum bilirubin levels and risk of colorectal cancer in Korean adults: results
from the Korean Genome and Epidemiology Study-Health Examinee (KoGES-HEXA) Cohort
Study.
Br J Cancer. 2024 Oct 8. doi: 10.1038/s41416-024-02847. PubMedAbstract available
SEKHAR H, Kochhar R, Carrington B, Kaye T, et al Pre-treatment magnetic resonance imaging in anal cancer: large-scale evaluation
of mrT, mrN and novel staging parameters.
Br J Cancer. 2024;131:1137-1146. PubMedAbstract available
September 2024
AMODIO V, Vitiello PP, Bardelli A, Germano G, et al DNA repair-dependent immunogenic liabilities in colorectal cancer: opportunities
from errors.
Br J Cancer. 2024 Sep 13. doi: 10.1038/s41416-024-02848. PubMedAbstract available
BOLAND PM, Mukherjee S, Imanirad I, Vijayvergia N, et al TAS-102, Irinotecan, and bevacizumab in pre-treated metastatic colorectal cancer
(TABAsCO), a phase II clinical trial.
Br J Cancer. 2024 Sep 7. doi: 10.1038/s41416-024-02845. PubMedAbstract available
CHOWDHURY S, Xiu J, Ribeiro JR, Nicolaides T, et al Consensus molecular subtyping of metastatic colorectal cancer expands
biomarker-directed therapeutic benefit for patients with CMS1 and CMS2 tumors.
Br J Cancer. 2024 Sep 4. doi: 10.1038/s41416-024-02826. PubMedAbstract available
August 2024
GWENZI T, Schrotz-King P, Anker SC, Schottker B, et al Prognostic value of post-operative iron biomarkers in colorectal cancer:
population-based patient cohort.
Br J Cancer. 2024 Aug 27. doi: 10.1038/s41416-024-02814. PubMedAbstract available
July 2024
SEGAL NH, Tie J, Kopetz S, Ducreux M, et al COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with
chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal
cancer.
Br J Cancer. 2024 Jul 25. doi: 10.1038/s41416-024-02796. PubMedAbstract available
LAWLER T, Hibler E, Walts ZL, Giurini L, et al Associations of diabetes and mortality among colorectal cancer patients from the
Southern Community Cohort Study.
Br J Cancer. 2024 Jul 19. doi: 10.1038/s41416-024-02787. PubMedAbstract available
HOU P, Shi P, Jiang T, Yin H, et al Correction: DKC1 enhances angiogenesis by promoting HIF-1alpha transcription and
facilitates metastasis in colorectal cancer.
Br J Cancer. 2024 Jul 17. doi: 10.1038/s41416-024-02801. PubMed
MASUI H, Kawada K, Itatani Y, Hirai H, et al Synergistic antitumor activity by dual blockade of CCR1 and CXCR2 expressed on
myeloid cells within the tumor microenvironment.
Br J Cancer. 2024;131:63-76. PubMedAbstract available
TSUKADA Y, Bando H, Inamori K, Wakabayashi M, et al Three-year outcomes of preoperative chemoradiotherapy plus nivolumab in
microsatellite stable and microsatellite instability-high locally advanced rectal
cancer.
Br J Cancer. 2024;131:283-289. PubMedAbstract available
June 2024
YANG L, Yi J, He W, Kong P, et al Correction: Death receptors 4/5 mediate tumour sensitivity to natural killer
cell-mediated cytotoxicity in mismatch repair deficient colorectal cancer.
Br J Cancer. 2024 Jun 26. doi: 10.1038/s41416-024-02768. PubMed
EXARCHAKOU A, Rachet B, Lyratzopoulos G, Maringe C, et al What can hospital emergency admissions prior to cancer diagnosis tell us about
socio-economic inequalities in cancer diagnosis? Evidence from population-based
data in England.
Br J Cancer. 2024;130:1960-1968. PubMedAbstract available
May 2024
YANG L, Yi J, He W, Kong P, et al Death receptors 4/5 mediate tumour sensitivitNot applicably to natural killer
cell-mediated cytotoxicity in mismatch repair deficient colorectal cancer.
Br J Cancer. 2024 May 25. doi: 10.1038/s41416-024-02673. PubMedAbstract available
ZWART K, van Nassau SCMW, van der Baan FH, Koopman M, et al Efficacy-effectiveness analysis on survival in a population-based real-world
study of BRAF-mutated metastatic colorectal cancer patients treated with
encorafenib-cetuximab.
Br J Cancer. 2024 May 20. doi: 10.1038/s41416-024-02711. PubMedAbstract available
VILLAREAL LB, Falcon DM, Xie L, Xue X, et al Hypoxia-inducible factor 3alpha1 increases epithelial-to-mesenchymal transition and
iron uptake to drive colorectal cancer liver metastasis.
Br J Cancer. 2024 May 1. doi: 10.1038/s41416-024-02699. PubMedAbstract available
QIAO L, Liu Y, Yang Q Comment on: "Neoadjuvant chemotherapy is noninferior to chemoradiotherapy for
early-onset locally advanced rectal cancer in the FOWARC trial".
Br J Cancer. 2024;130:1432-1433. PubMed
CAI J, Lin K, Luo T, Weng J, et al Neoadjuvant chemotherapy is noninferior to chemoradiotherapy for early-onset
locally advanced rectal cancer in the FOWARC trial.
Br J Cancer. 2024;130:1434-1440. PubMedAbstract available
MENG XN, Ma JF, Liu YH, Li SQ, et al Dynamic genomic changes in methotrexate-resistant human cancer cell lines beyond
DHFR amplification suggest potential new targets for preventing drug resistance.
Br J Cancer. 2024;130:1819-1827. PubMedAbstract available
KISAKOL B, Matveeva A, Salvucci M, Kel A, et al Identification of unique rectal cancer-specific subtypes.
Br J Cancer. 2024;130:1809-1818. PubMedAbstract available
April 2024
REE AH, Saltyte Benth J, Hamre HM, Kersten C, et al First-line oxaliplatin-based chemotherapy and nivolumab for metastatic
microsatellite-stable colorectal cancer-the randomised METIMMOX trial.
Br J Cancer. 2024 Apr 25. doi: 10.1038/s41416-024-02696. PubMedAbstract available
RIO-VILARINO A, Cenigaonandia-Campillo A, Garcia-Bautista A, Mateos-Gomez PA, et al Correction: Inhibition of the AURKA/YAP1 axis is a promising therapeutic option
for overcoming cetuximab resistance in colorectal cancer stem cells.
Br J Cancer. 2024 Apr 4. doi: 10.1038/s41416-024-02667. PubMed
BARANYI M, Molnar E, Hegedus L, Gabriel Z, et al Farnesyl-transferase inhibitors show synergistic anticancer effects in
combination with novel KRAS-G12C inhibitors.
Br J Cancer. 2024;130:1059-1072. PubMedAbstract available
TIAN Y, Lin Y, Qu C, Arndt V, et al Genetic risk impacts the association of menopausal hormone therapy with
colorectal cancer risk.
Br J Cancer. 2024 Apr 1. doi: 10.1038/s41416-024-02638. PubMedAbstract available
March 2024
FELIU J, Gamez-Pozo A, Martinez-Perez D, Perez-Wert P, et al Functional proteomics of colon cancer Consensus Molecular Subtypes.
Br J Cancer. 2024 Mar 14. doi: 10.1038/s41416-024-02650. PubMedAbstract available
ZHANG X, He Y, Li X, Shraim R, et al Circulating 25-hydroxyvitamin D and survival outcomes of colorectal cancer:
evidence from population-based prospective cohorts and Mendelian randomisation.
Br J Cancer. 2024 Mar 13. doi: 10.1038/s41416-024-02643. PubMedAbstract available
RIO-VILARINO A, Cenigaonandia-Campillo A, Garcia-Bautista A, Mateos-Gomez PA, et al Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for
overcoming cetuximab resistance in colorectal cancer stem cells.
Br J Cancer. 2024 Mar 11. doi: 10.1038/s41416-024-02649. PubMedAbstract available
DENG LQ, Shi CJ, Zhou ST, Zeng WQ, et al EIF4A3-negatively driven circular RNA beta-catenin (circbeta-catenin) promotes
colorectal cancer progression via miR-197-3p/CTNND1 regulatory axis.
Br J Cancer. 2024 Mar 8. doi: 10.1038/s41416-024-02612. PubMedAbstract available
GOURIOU C, Lemanski C, Pommier P, Le Malicot K, et al Management of non-metastatic anal cancer in the elderly: ancillary study of the
French multicenter prospective cohort FFCD-ANABASE.
Br J Cancer. 2024;130:769-776. PubMedAbstract available
February 2024
KARAPETIS CS, Liu H, Sorich MJ, Pederson LD, et al Fluoropyrimidine type, patient age, tumour sidedness and mutation status as
determinants of benefit in patients with metastatic colorectal cancer treated
with EGFR monoclonal antibodies: individual patient data pooled analysis of
randomised trials fro
Br J Cancer. 2024 Feb 24. doi: 10.1038/s41416-024-02604. PubMedAbstract available